-+ 0.00%
-+ 0.00%
-+ 0.00%

Anixa advances ovarian cancer CAR-T trial to highest dose cohort in Phase 1 study

PUBT·07/06/2026 12:32:13
Listen to the news
Anixa advances ovarian cancer CAR-T trial to highest dose cohort in Phase 1 study
  • Anixa treated the first patient in Cohort 5 of its Phase 1 FSHR-targeted CAR-T/CER-T trial for recurrent ovarian cancer.
  • Cohort 5 dosing rose to 10,000,000 CAR-positive cells/kg following lymphodepletion, the highest level tested in the study.
  • No dose-limiting toxicities reported across cohorts through the prior 3,000,000 cells/kg dose level.
  • Five treated patients have survived more than one year post-treatment, including one beyond two years.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607060830PR_NEWS_USPR_____LA97567) on July 06, 2026, and is solely responsible for the information contained therein.